Cancer Cell International最新文献

{"title":"Intratumoral microbiota for hepatocellular carcinoma: from preclinical mechanisms to clinical cancer treatment.","authors":"Muhua Chen, Lei Bie","doi":"10.1186/s12935-025-03745-7","DOIUrl":"https://doi.org/10.1186/s12935-025-03745-7","url":null,"abstract":"<p><p>Intratumoral microbiota has been found to be a crucial component of hepatocellular carcinoma (HCC). Due to insufficient recognition, technical limitations, and low biomass of intratumoral microbiota, it is poorly understood. Intratumoral microbiota exhibit significant diversity in HCC tissues. It is involved in the development of HCC through several mechanisms, such as remodeling the immunosuppressive microenvironment, metabolic reprogramming, and genetic alterations. Moreover, intratumoral microbiota is associated with the metastasis of HCC cells. Herein, we reviewed the history of intratumoral microbiota, applied biotechnology to depict the signatures of intratumoral microbiota, investigated the potential sources of intratumoral microbiota, and assessed their functions, mechanisms, and heterogeneity. Furthermore, in this review, we summarized the development of therapeutics that can be used in the treatment of HCC and proposed future perspectives for research in this field.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"152"},"PeriodicalIF":5.3,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12007317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of modified bleomycin administration with EP chemotherapy in adult male patients with germ cell tumors: a retrospective study.","authors":"Ditian Shu, Riqing Huang, Meiting Chen, Haifeng Li, Xin An, Cong Xue, Anqi Hu, Fangjian Zhou, Kai Yao, Zhuowei Liu, Yanxia Shi","doi":"10.1186/s12935-025-03774-2","DOIUrl":"https://doi.org/10.1186/s12935-025-03774-2","url":null,"abstract":"<p><strong>Background: </strong>Given the substantial inconvenience caused by weekly bleomycin administration, we initiated a study to evaluate the efficacy and toxicity of the modified bleomycin combined with EP (modified-BEP) regimen in Chinese adult male patients with germ cell tumors (GCTs).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 274 adult male GCT patients treated with modified-BEP at the Sun Yat-sen University Cancer Center between 2005 and 2022. The regimen involved a tri-weekly 5-day schedule with 30 IU modified bleomycin (administered on days 1, 3, and 5), 20 mg/m2 cisplatin (days 1-5), and 100 mg/m2 etoposide (days 1-5). The survival rates and safety profiles of the patients were analyzed.</p><p><strong>Results: </strong>Among the patients, 42 patients received BEP in adjuvant setting, while 232 were treated with BEP in curative setting. With a median follow-up of 41.03 months among the curative patient population, the 5-year progression-free survival (PFS) rate was 79.33%, and the 5-year overall survival (OS) rate was 86.26%. Stratified by the International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic groups, the 5-year OS rates of the good, intermediate, and poor risk groups were 99.05%, 92.84%, and 55.96% (P < 0.0001), respectively. Favorable responses, including complete remission and partial response with negative tumor markers, were achieved in 91.07% of good-risk, 84.13% of intermediate-risk, and 52.63% of poor-risk patients, with a significant difference (P < 0.0001). Multivariate analysis indicated that non-seminoma, poor risk group, mediastinal primary tumor, and Eastern Cooperative Oncology Group (ECOG) 2 status were significantly associated with inferior PFS. In the entire cohort, major grade 3-4 adverse events included neutropenia (38.69%), anemia (4.74%), thrombocytopenia (5.11%), and febrile neutropenia (6.2%), with no death due to pulmonary toxicity.</p><p><strong>Conclusion: </strong>The modified-BEP regimen showed an effective and tolerable treatment alternative for adult male GCT patients in China, offering greater convenience compared to the standard BEP regimen.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"151"},"PeriodicalIF":5.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12004817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbonyl reductase 4 suppresses colorectal cancer progression through the DNMT3B/CBR4/FASN/mTOR axis.","authors":"Jingjing Zhang, Tiaotiao Chen, Wencheng Wu, Chunhua Hu, Bangting Wang, Xiaofeng Jia, Mujie Ye","doi":"10.1186/s12935-025-03776-0","DOIUrl":"https://doi.org/10.1186/s12935-025-03776-0","url":null,"abstract":"<p><p>Lipid metabolism is implicated in the initiation and progression of human colorectal cancer (CRC). Carbonyl reductase 4 (CBR4), a member of the carbonyl reductase family, plays a role in the biosynthesis of fatty acids. However, its involvement in CRC remains poorly understood. In this study, we aim to explore the function of CBR4 in CRC. Our findings indicated that the expression of CBR4 was significantly reduced in CRC tissues. Functional analyses revealed that CBR4 functions to inhibit cell proliferation, colony formation, migration, invasion, and tumor growth in vivo. Mechanistically, CBR4 interacts with fatty acid synthase (FASN), activating the ubiquitin-proteasome pathway, which leads to a reduction in FASN expression, thereby inhibiting the mTOR pathway and curtailing CRC development. Orlistat, a known FASN inhibitor, demonstrated anti-cancer properties both in vitro and in vivo. Additionally, DNMT3B, a DNA methyltransferase, contributed to the down-regulation of CBR4 by inducing methylation in the promoter region. In summary, our findings suggest that the DNMT3B/CBR4/FASN/mTOR signaling pathway is crucial in the advancement of CRC, and elucidate the potential mechanism by which enzymatic carbonyl reduction and lipid metabolism may be connected to CRC progression, offering a novel therapeutic strategy for its clinical management.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"146"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear-activating miRNAs: unveiling the intricacies of subcellular miRNA function and regulation in cancer and immunity disease.","authors":"Xiang Ren, Gang Liu, Jianping Zhou","doi":"10.1186/s12935-025-03760-8","DOIUrl":"https://doi.org/10.1186/s12935-025-03760-8","url":null,"abstract":"<p><p>MicroRNAs (miRNAs) are small non-coding RNAs that traditionally recognized as negative regulators of gene expression through post-transcriptional regulation in the cytoplasm. However, recent discoveries have unveiled some novel miRNA functions in the cell nucleus, where a subset of miRNAs, termed nuclear-activating miRNAs (NamiRNAs), play pivotal roles in gene activation and transcriptional regulation for cancer and immunity disease. The discovery of NamiRNAs demonstrated a complementary regulatory function of miRNA, showing their differential activities in the nucleus and cytoplasm. This review aims to explore the biogenesis, mechanisms, and regulatory functions of NamiRNAs, deciphering their involvement in NamiRNA-gene network for gene expression modulation, and emerging significance as drug targets against cancer.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"147"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A diagnostic model for non-invasive urothelial cancer early detection based on methylation of urinary tumor DNA.","authors":"Ningning Wu, Zhen Wu, Yanwen Wang, Anqi Zhang, Yongfei Peng, Yan Cheng, Hongsong Lei, Siwen Liu, Jie Zhao, Tianbao Li, Guangpeng Zhou","doi":"10.1186/s12935-025-03766-2","DOIUrl":"https://doi.org/10.1186/s12935-025-03766-2","url":null,"abstract":"<p><strong>Background: </strong>Diagnostic methods for urothelial cancer (UC) are often invasive, while urinary cytology, a non-invasive alternative, suffers from limited sensitivity. This study aimed to identify differentially methylated markers in urinary tumor DNA and develop a diagnostic method to enhance the sensitivity of non-invasive UC detection.</p><p><strong>Methods: </strong>Whole-genome bisulfite sequencing and deep methylation sequencing were employed to identify significantly hypermethylated UC-associated genes in clinical samples and public UC datasets. Further screening was conducted using tumor biopsies and urine samples from patients, leading to the selection of three hypermethylated UC markers. A diagnostic model based on these markers was constructed and validated in a cohort (N = 432) comprising patients with UC, other cancers, benign lesions, and non-UC urinary tract diseases.</p><p><strong>Results: </strong>Validation in a cohort of 432 subjects demonstrated that the UC diagnostic model, incorporating three hypermethylated markers (VIM, TMEM220, and PPM1N), achieved an overall sensitivity of 94.44% in 108 UC patients. Specificities were 96.34%, 90.76%, and 87.72% in 191 non-neoplastic individuals, 76 patients with benign lesions, and 57 patients with other cancers, respectively, resulting in an overall specificity of 93.52%. Methylation level analysis revealed significantly higher methylation (P < 0.001) for three markers in UC samples compared to non-UC samples. Furthermore, the model exhibited sensitivities of 80% and 88.57% for detecting stage 0a/0is and stage I UC, respectively.</p><p><strong>Conclusions: </strong>The UC diagnostic model demonstrates excellent diagnostic performance, particularly in the early detection of UC. This non-invasive approach, characterized by high sensitivity and specificity, holds significant potential for further clinical evaluation and development as a reliable tool for UC diagnosis using urine samples.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"148"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic strength: unleashing exercise and polyphenols against breast cancer.","authors":"Haifan Pang, Bita Badehnoosh","doi":"10.1186/s12935-025-03767-1","DOIUrl":"https://doi.org/10.1186/s12935-025-03767-1","url":null,"abstract":"<p><p>Breast cancer remains a major global health challenge, necessitating innovative preventive and therapeutic strategies. Emerging evidence such as clinical trials suggests that the combination of exercise and polyphenol intake exerts synergistic effects in mitigating breast cancer progression by modulating key molecular pathways. Exercise enhances immune function, reduces inflammation, and regulates cellular metabolism, while polyphenols, natural compounds found in various plant-based foods, exhibit antioxidant, anti-inflammatory, and anti-carcinogenic properties. Together, these interventions influence apoptosis, oxidative stress, and ferroptosis which play crucial roles in breast cancer pathophysiology. This review explores the molecular mechanisms underlying the combined impact of exercise and polyphenols on breast cancer prevention and treatment. Understanding the interplay between exercise and polyphenols at the molecular level could pave the way for novel, non-invasive therapeutic strategies. Future research should focus on optimizing exercise regimens and dietary interventions to maximize their anti-cancer benefits. By bridging molecular insights with clinical applications, this review aims to provide a foundation for incorporating lifestyle-based interventions into breast cancer management. Our findings collectively highlight the promising potential of combining curcumin supplementation with exercise as a multifaceted approach to breast cancer treatment. The synergistic effects observed in various studies suggest that integrating lifestyle modifications with dietary interventions may enhance therapeutic efficacy and mitigate cancer progression. Further clinical investigations are warranted to validate these results and explore their applicability in human subjects. The evidence supports a holistic strategy for breast cancer management that could improve patient outcomes and quality of life during treatment.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"144"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing exosomes for targeted drug delivery systems to combat brain cancer.","authors":"Abdullah E Basyoni, Amira Atta, Maha M Salem, Tarek M Mohamed","doi":"10.1186/s12935-025-03731-z","DOIUrl":"https://doi.org/10.1186/s12935-025-03731-z","url":null,"abstract":"<p><p>Brain cancer remains a significant challenge in the field of oncology, primarily because of its aggressive nature and the limited treatment options available. Conventional therapies often fall short in effectively targeting tumor cells, while sparing healthy brain tissue from collateral damage. However, exosomes are now recognized as promising nanocarriers for targeted drug delivery. These naturally occurring extracellular vesicles can cross the blood-brain barrier and selectively interact with cancer cells. Utilizing exosomes as drug delivery vehicles offers a novel approach with significant potential for targeted therapy. By encapsulating therapeutic agents within exosomes, drugs can be specifically targeted to tumor cells, maximizing their impact whilst minimizing damage to healthy brain tissue. Furthermore, exosomes can be modified to display molecules that specifically recognize and bind to cancer cells, further enhancing their precision and efficacy. While exosome-based therapies show potential, scalability, purification, and clinical application challenges remain. The scalability of exosome production, purification, and modification techniques remains a hurdle that must be overcome for clinical translation. Additionally, the intricate interactions between the tumor microenvironment and exosomes necessitate further research to optimize therapeutic outcomes. The review explores applications and future perspectives of exosome-based therapies in advancing targeted brain cancer treatment.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"150"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miR-126: a bridge between cancer and exercise.","authors":"Zhengqiong Liu, Shanbin Ke, Yuwen Wan","doi":"10.1186/s12935-025-03784-0","DOIUrl":"https://doi.org/10.1186/s12935-025-03784-0","url":null,"abstract":"<p><p>The microRNA miR-126 supports endothelial cells and blood vessel integrity. Recent research has shown that it also serves as a key link between exercise and cancer. This article delves into how exercise affects the expression of miR-126, impacting cardiovascular well-being and metabolic control. The article also examines the various contributions of miR-126 in cancer, acting as both a suppressor and an enhancer depending on the particular context. Regular aerobic exercises, including HIIT, consistently increase levels of miR-126, leading to enhanced angiogenesis, endothelial repair, and improved vascular function through mechanisms involving VEGF, HIF-1α, and EPC mobilization. Resistance training affects similar pathways, but does not cause a significant change in miR-126 levels.MiR-126 involves in cancer by suppressing tumor growth and controlling key pathways such as PI3K/Akt, ERK/MAPK, and EMT. Lower levels are associated with negative outcomes, later stages of the disease, and increased spread of different types of cancer like glioblastoma, CRC, ovarian, esophageal, gastric, and prostate cancer.The relationship between exercise and cancer suggests a possible therapeutic approach, where the regulation of miR-126 through exercise could help improve vascular function and slow tumor growth. Further studies should focus on understanding the specific molecular pathways through which miR-126 connects these areas, leading to potential interventions that utilize its regulatory network to promote cardiovascular well-being and enhance cancer treatment.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"145"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming.","authors":"Mina Afrashteh Nour, Mansour Rajabivahid, Marjan Sadat Seyed Mehdi, Safa Tahmasebi, Sepideh Nasirzadeh Dashtgol, Mahmoud Dehghani-Ghorbi, Ahmad Ghorbani Vanan, Farid Ghorbaninezhad","doi":"10.1186/s12935-025-03781-3","DOIUrl":"https://doi.org/10.1186/s12935-025-03781-3","url":null,"abstract":"<p><p>Melanoma, being one of the most dangerous forms of skin cancer, is characterized by its aggressive and metastatic nature, with the potential to develop resistance to various treatments. This resistance makes the disease challenging to treat, emphasizing the need for new treatment strategies. Within the tumor microenvironment (TME), melanoma cells exploit metabolic shifts, particularly glycolysis, to create an immunosuppressive TME that prevents dendritic cells (DCs) from functioning properly. Essential metabolic alterations such as lactate and lipid accumulation, and lack of tryptophan disrupt DC maturation, antigen presentation, and T cell activation. In recent years, melanoma immunotherapy has increasingly focused on reprogramming the metabolism of DCs. This review paper aims to provide insights into the metabolic suppression of melanoma-associated DCs, allowing the design of therapeutic strategies based on metabolic interventions to promote or restore DC function. This contribution reviews the metabolic reprogramming of DCs as a new approach for melanoma immunotherapy.</p>","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"149"},"PeriodicalIF":5.3,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Chinese prospective cohort research developed and validated a risk prediction model for patients with cervical cancer.","authors":"Li Yuan, Baogang Wen, Xiuying Li, Haike Lei, Dongling Zou, Qi Zhou","doi":"10.1186/s12935-025-03744-8","DOIUrl":"https://doi.org/10.1186/s12935-025-03744-8","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Cervical cancer constitutes a formidable health challenge imperiling the well-being and lives of women globally, particularly in underdeveloped nations. The survival rates among patients diagnosed with cervical cancer manifest considerable heterogeneity, shaped by a myriad of variables. Within the scope of this inquiry, a predictive model for projecting overall survival (OS) in cervical cancer patients was formulated and subsequently validated.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Clinicopathological and follow-up information of patients diagnosed with cervical cancer were prospectively collected from May 1, 2015, to December 12, 2019, as part of an ongoing longitudinal cohort study conducted at Chongqing University Cancer Hospital. Subsequent to the acquisition of follow-up data, the sample was randomly divided into two cohorts: a training cohort (n = 2788) and a testing cohort (n = 1194). The predictors for the model were selected through least absolute shrinkage and selection operator (LASSO) regression analysis. Cox stepwise regression analysis was then employed to identify independent predictive indicators. The study results were subsequently presented in the form of static and web-based dynamic nomograms. To elucidate the objective validation of the prognosis and anticipated survival, the concordance index (C-index) was computed. The model's discriminatory ability across various variables and its predictive performance were assessed through calibration plots. Additionally, the predictive model's capacity for outcome prediction and its net benefit were evaluated using the Net Reclassification Index (NRI) and Decision Curve Analysis (DCA) curves.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The final model regarded the following variables from the training cohort as independent risk factors for cervical cancer patients: age, medical insurance, pathology, HPV infection status, chemotherapy, β2-microglobulin, neutrophil-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR). The C-indices of OS for the training group were 0.769 (95% CI, 0.748-0.789) and for the testing cohort were 0.779 (95% CI, 0.751-0.808). In both the training and testing cohorts, the calibration curve for estimating the chance of survival exhibited a significant agreement between prediction by nomogram and actual observation. In the training cohort, the areas under the curve (AUC) of the receiver operating characteristic (ROC) curves for 1-year, 3-year, and 5-year OS were 0.811, 0.760, and 0.782, respectively, while in the testing cohort, they were 0.818, 0.780, and 0.778, respectively. The Net Reclassification Index (NRI) and Decision Curve Analysis (DCA) provided evidence of the model's superior predictive ability and net benefit when compared to the FIGO Staging system.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The prediction methods effectively forecasted the outcomes of cervical cancer patients. Due to the model's excellent calibration and discrimination, it ","PeriodicalId":9385,"journal":{"name":"Cancer Cell International","volume":"25 1","pages":"142"},"PeriodicalIF":5.3,"publicationDate":"2025-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11995461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}